Notice NOT-HG-25-016 from the NIH Guide for Grants and Contracts

Notice NOT-HG-25-015 from the NIH Guide for Grants and Contracts

Notice NOT-EY-25-004 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-064 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-25-147 from the NIH Guide for Grants and Contracts. This NOFO invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this NOFO. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

Funding Opportunity PAR-25-329 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support the discovery and development of medications to prevent and treat substance use disorders (SUDs) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this NOFO must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat SUDs and overdose. The compounds to be evaluated can be small molecules, biologics, or natural products. They can be tested in pre-clinical models and/or for the clinical manifestations of SUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of SUDs and overdose. Through this NOFO, NIDA seeks to fast-track the discovery and development of medications to prevent and treat SUDs or overdose and to advance them in the FDA's drug development approval pipeline.

Funding Opportunity PAR-25-328 from the NIH Guide for Grants and Contracts. The purpose of this notice of Funding Opportunity (NOFO) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.

Notice NOT-NR-25-009 from the NIH Guide for Grants and Contracts

GBP 56,000.00 per year: Genomics England: Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the caus Cambridge, United Kingdom

GBP 68,000.00 per year: Genomics England: Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the caus Cambridge, United Kingdom

Funding Opportunity PA-25-280 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grants (T35) to eligible, domestic institutions to develop and/or enhance research training opportunities for predoctoral students interested in careers within biomedical, behavioral, or clinical research workforce. Many NIH Institutes and Centers (ICs) use this NRSA program exclusively to support intensive, short-term research training experiences for health professional students (medical students, veterinary students, and/or students in other health-professional programs) during the summer. This program is also intended to encourage training of graduate students in the physical or quantitative sciences to pursue interests in research careers by short-term exposure to, and involvement in, the health-related sciences. The training should be of sufficient depth to enable the trainees, upon completion of the program, to have a thorough exposure to the principles underlying the conduct of biomedical research.

Funding Opportunity PAR-25-357 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to fund meritorious vision-related research projects that involve secondary data analyses using existing database resources. The development of statistical methodology necessary for improving methods to analyze vision health data using existing vision data may also be proposed.

Funding Opportunity PAR-25-347 from the NIH Guide for Grants and Contracts. The goal of this NOFO is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here (https://www.drugabuse.gov/funding/funding-priorities) or within the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031).

Notice NOT-GM-25-018 from the NIH Guide for Grants and Contracts

Competitive: T-Therapeutics Limited: About the Company T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases. Ba Cambridge, United Kingdom

Competitive: Northreach: About the job Senior/Lead Bioinformatician (Mass Spectrometry Analysis) - Hybrid Northreach is a dynamic recruitment agency that connects businesse Oxford, United Kingdom

GBP 49,250.00 - 55,295.00 per year: University of Bristol Law School: The role The School of Biological Sciences is seeking to appoint a Pathway 3 Lecturer (grade K), as the operational lead of our highly successful Bio Bristol, United Kingdom

Competitive: Manchester University NHS Foundation Trust: Job summary We are seeking a state registered Clinical Scientist Bioinformatics (Genomics) or an STP trainee graduating this year to join our team in Manchester, United Kingdom

Funding Opportunity RFA-CA-25-006 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or device developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Funding Opportunity RFA-CA-25-007 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI P50 specialized centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or device developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.